Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study.
Cesar Giron-HernandezJoong Hee HanRoberta AlberioArun SinghMaria Paz García-PortillaMaurizio PompiliR Karl KnightUte RicharzSrihari GopalJosé AntunesPublished in: Neuropsychiatric disease and treatment (2023)
The efficacy of PP6M was non-inferior to that of PP3M in preventing relapse in the European subgroup previously treated with PP1M or PP3M, which was consistent with the global study. No new safety signals were identified.